HERBALIFE LTD. (HLF): Results of Operations and Financial Condition
HERBALIFE LTD. (HLF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030059301ex99-1.htm PRESS RELEASE ISSUED BY HERBALIFE LTD. ON AUGUST 5, 2026 Exhibit 99.1 CONFIDENTIAL & PRIVILEGED Herbalife Reports Second Quarter Net Sales Growth; Marks Fourth Consecutive Quarter of Topline Expansion; Net Sales and Adjusted EBITDA 1 Exceed Guidanc
How this was made
The 30-second read
Why it matters
Traders can update valuation and positioning based on the revised full-year guidance ranges and the explicit FX headwind framing, while also monitoring execution risk around new product launches and platform diagnostics integration.
Market read
Fresh Q2 print and revised FY 2026 guidance (net sales and adjusted EBITDA range tightened) provide a direct expectation reset for HLF.
What to watch
Non-GAAP metrics (adjusted EBITDA, adjusted net income) and the magnitude of inventory write-downs and other costs could be scrutinized for sustainability, especially alongside the CFO transition.
Background
The 8-K includes Exhibit 99.1 with Q2 2026 results, product and platform updates (Bioniq GO, Pro2col beta, at-home diagnostics beta), and a planned CFO transition effective Jan 1, 2027.
Ticker impact
Herbalife reports Q2 net sales $1.3B (+5.4% YoY) and raises/adjusts full-year 2026 guidance, tightening adjusted EBITDA to $670M-$690M.
Moderate positive bias for the next session, with follow-through risk if investors focus on FX-driven back-half weakness or margin compression.
The filing is a fresh 8-K with quantified results and revised full-year ranges, which typically moves expectations. However, the article emphasizes FX headwinds and margin down 120 bps, limiting upside conviction.
Market effects
Adds datapoint on consumer health/personalized nutrition demand and margin sensitivity to FX for direct-selling/health supplement peers.
Highlights North America and EMEA expansion via events and Bioniq GO rollout, which may influence regional distributor sentiment.
FX-driven guidance language underscores currency sensitivity for multinational consumer brands, relevant for cross-border peers.
Counterpoint
Investors may discount the constant-currency strength and focus on reported net loss, gross margin down, and FX headwinds that still pressure the back half.
Key entities
- issuerHerbalife Ltd.
Reports Q2 2026 results and revises full-year 2026 guidance; announces CFO transition and product/platform initiatives.
- executiveJohn DeSimone
CFO at time of filing, quoted on results; planned retirement at year-end.
- executiveScott Schaefer
Named successor CFO, effective Jan 1, 2027.
